![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Raskin Philip Mohan Alok
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.15, Iss.2, 2010-06, pp. : 225-236
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus
By Petrovsky N. Silva D. Schatz D.A.
Pediatric Drugs, Vol. 5, Iss. 9, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus
By Petrovsky N.
Drugs, Vol. 62, Iss. 18, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Type 1 diabetes prevention trials: the debate rages on
Inpharma, Vol. 1, Iss. 1395, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Simulation Model for Estimating Direct Costs of Type 1 Diabetes Prevention
By Hahl J.
PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. :